OpenCareby Vivonco
Search/
Talk to us Review a case
Menu
Skip to content
Weekly roundup · Sunday, November 15, 2026

The week's 3 biggest stories

All 54 stories from the week are below, by topic.

  1. FDA approves durvalumab combination before and after surgery for bladder cancerFDA approval · The FDA approved the immunotherapy durvalumab with the antibody-drug conjugate enfortumab vedotin before surgery, followed by durvalumab, for adults with muscle-invasive bladder cancer who cannot or will not take cisplatin.
  2. FDA approves kinase inhibitor for tenosynovial giant cell tumorFDA approval · The FDA approved the kinase inhibitor pimicotinib for adults with symptomatic tenosynovial giant cell tumor when surgery could cause serious harm.
  3. Personalized therapy intismeran reduced recurrence in skin cancerPhase III trial · In a phase 3 trial, people with high-risk skin cancer removed by surgery received pembrolizumab with personalized therapy intismeran or placebo.

Clinical trials

Precision oncology

Antibody-drug conjugates

Antibodies

India access

Cancer vaccines

Cancer-care delivery

Cell and gene therapy

Head and neck cancer

Cell therapy

Other